Overview
Emmanuelle Trombe represents pharmaceutical, medical device and bio-pharmaceutical companies globally in transactional matters in relation to M&A and divestitures, joint ventures and strategic partnerships, large-scale projects, outsourcing projects, product development, licensing agreements and regulatory matters. She also advises venture capital funds and bio-pharmaceutical companies in connection with a broad range of financing activities. Emmanuelle is a co-head of the Firm’s Life Sciences Group and serves as an elected member of the Firm’s Management Committee.
Emmanuelle is distinguished in Chambers Europe and Legal 500 EMEA in life sciences transactions, where she is highly recommended for her experience in the pharmaceutical, healthcare, biotech and medical devices industries and described as very responsive, smart, flexible and business-minded. She has been distinguished as the Lawyer of the Year in Life Sciences for 2024.
Results
- Advised Orano Med its in collaboration with Molecular Partners to co-develop novel Radio-DARPin therapeutics (RDTs) that use Orano Med’s 212Pb radioisotope as a payload to selectively kill cancer cells
- Advised Pierre Fabre in the acquisition of Kinnate Biopharma’s investigational pan-RAF inhibitor, Exarafenib, and other pan-RAF program assets
- Advised Owkin on funding to launch Bioptimus, the first universal AI model designed to fuel breakthrough discoveries and accelerate innovation in biomedicine
- Advised Sensorion, a pioneering clinical-stage biotechnology company specializing on the development of new therapies to restore, treat and prevent hearing loss disorders, on its new financing of over EUR 50 million from existing and new investors specializing in the healthcare sector
- Advised Novartis Groupe France SAS in the sale of the company CellforCure and its cell and gene therapy development and production site in Les Ulis, France, to Seqens SAS
- Advised Aqemia, a pioneering pharmatech company leveraging AI and quantum-inspired physics to accelerate the discovery of small molecule drug candidates with higher probability of success in the clinic, in its multi-year research collaboration with Sanofi
- Advised Servier in the acquisition from CStone of the exclusive rights to develop and commercialize TIBSOVO® (ivosidenib tablets) in Greater China and Singapore
- Advised Pierre Fabre, a major French dermo-cosmetic and pharmaceutical group, on the negotiation and conclusion of a collaboration and license agreement with Scorpion Therapeutics to codevelop two next-generation epidermal growth factor receptor (EGFR) inhibitors
- Advised Owkin, which develops artificial intelligence solutions for medical research, on a multi-year strategic collaboration agreement with US laboratory Bristol Myers Squibb (BMS)
- Advised Dynacure, on its cross-border merger with the Belgian company Flamingo Therapeutics, to create a leading RNA therapeutics company focused on clinical oncology
- Advised Innate Pharma SA on an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates with a primary focus in Celiac disease
- Represented Innate Pharma on its global co-development and commercialization agreement with AstraZeneca for IPH2201, a novel antibody in Phase II development for the treatment of cancer
- Represented Pierre Fabre on its collaboration and licensing agreement with Array Biopharma for the development and commercialization of two novel oncology products, Binimetinib and Encorafenib
- Represented DBV Technologies on its US$281.5 million offering on NASDAQ
Recognitions
- Best Lawyers in France, ‘Lawyer of the Year’ in Biotechnology and Life Sciences, 2021-2024
- Chambers Europe, , Band 1 in France: Pharma/Life Sciences, 2014-2024
- The Legal 500 EMEA, Leading Individual in France: Healthcare and Life Sciences, 2022-2024
- IFLR1000, M&A, 2022-2023
Community
- Médecins sans Frontières, regularly provides contractual advice to this international humanitarian medical association
